Biologics in SAPHO syndrome: A systematic review
dc.creator | Daoussis D., Konstantopoulou G., Kraniotis P., Sakkas L., Liossis S.-N. | en |
dc.date.accessioned | 2023-01-31T07:50:27Z | |
dc.date.available | 2023-01-31T07:50:27Z | |
dc.date.issued | 2019 | |
dc.identifier | 10.1016/j.semarthrit.2018.04.003 | |
dc.identifier.issn | 00490172 | |
dc.identifier.uri | http://hdl.handle.net/11615/73070 | |
dc.description.abstract | Background: The SAPHO syndrome is a relatively rare clinical entity characterized by a wide range of dermatological and musculoskeletal manifestations. Biologics have been used in cases refractory to conventional treatment. Methods: We present herein a patient with refractory to treatment SAPHO syndrome who exhibited a dramatic and fast response to IL-17 blockade. Additionally, we performed a systematic review of all cases of patients with SAPHO syndrome treated with biologics to date. Results: We identified 66 cases treated with biologics (45 with TNF blockers, 7 with IL-1 blockers, 13 with biologics targeting the IL-23/IL-17 axis, and 1 with tocilizumab). Data support a positive effect of anti-TNF treatment in SAPHO with a response rate in bone and joint manifestations of 93.3%. Skin disease also improved in 21/29 cases (72.4%). Data related to IL-1 inhibition in SAPHO are encouraging with most patients exhibiting a significant response in musculoskeletal manifestations (6/7, 85.7%). However, IL-1 inhibition is not effective in skin manifestations. Ustekinumab seems to have some efficacy with 2/4 patients responding in skin and 3/5 in bone/joint manifestations. Data related to IL-17 blockade indicate efficacy in skin disease with 4/7 patients responding (57.1%). Joint/bone manifestations improved in 3/8 patients (37.5%). Conclusions: In SAPHO patients not responding to conventional treatment, TNF blockers appear to be the first choice. In patients failing TNF blockers, IL-1 inhibitors and biologics targeting the IL-17/IL-23 axis could be used. © 2018 Elsevier Inc. | en |
dc.language.iso | en | en |
dc.source | Seminars in Arthritis and Rheumatism | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85047192201&doi=10.1016%2fj.semarthrit.2018.04.003&partnerID=40&md5=cde7820a1c435b2a747c832ada9f1758 | |
dc.subject | adalimumab | en |
dc.subject | biological product | en |
dc.subject | certolizumab pegol | en |
dc.subject | infliximab | en |
dc.subject | methotrexate | en |
dc.subject | secukinumab | en |
dc.subject | tocilizumab | en |
dc.subject | tumor necrosis factor inhibitor | en |
dc.subject | ustekinumab | en |
dc.subject | biological product | en |
dc.subject | immunosuppressive agent | en |
dc.subject | adult | en |
dc.subject | biological therapy | en |
dc.subject | bone biopsy | en |
dc.subject | case report | en |
dc.subject | clinical article | en |
dc.subject | clinical feature | en |
dc.subject | disease exacerbation | en |
dc.subject | drug efficacy | en |
dc.subject | drug response | en |
dc.subject | drug withdrawal | en |
dc.subject | female | en |
dc.subject | human | en |
dc.subject | human tissue | en |
dc.subject | liver toxicity | en |
dc.subject | middle aged | en |
dc.subject | pain intensity | en |
dc.subject | priority journal | en |
dc.subject | Review | en |
dc.subject | SAPHO syndrome | en |
dc.subject | skin defect | en |
dc.subject | steroid therapy | en |
dc.subject | thorax pain | en |
dc.subject | treatment duration | en |
dc.subject | treatment response | en |
dc.subject | SAPHO syndrome | en |
dc.subject | treatment outcome | en |
dc.subject | Acquired Hyperostosis Syndrome | en |
dc.subject | Biological Products | en |
dc.subject | Humans | en |
dc.subject | Immunosuppressive Agents | en |
dc.subject | Treatment Outcome | en |
dc.subject | W.B. Saunders | en |
dc.title | Biologics in SAPHO syndrome: A systematic review | en |
dc.type | other | en |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |